NCT03905109View on ClinicalTrials.gov

Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 19, 2022

Primary Completion Date

September 19, 2022

Study Completion Date

September 19, 2022

Conditions
Crohn Disease
Interventions
DRUG

ABX464

ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.

DRUG

Placebo

In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.

Trial Locations (1)

3000

University Hospitals Leuven - campus Gasthuisberg, Leuven

Sponsors

Lead Sponsor

Abivax S.A.
All Listed Sponsors
lead

Abivax S.A.

INDUSTRY